Tempest Therapeutics stock soars 4,000% on updated data (NASDAQ:TPST)

Shares of Tempest Therapeutics (NASDAQ:TPST) closed nearly 4,000% higher Wednesday after the company released updated data from a Phase 1/2 study of its drug TPST-1120 in the first-line treatment of advanced or metastatic hepatocellular carcinoma, a type of liver cancer. The stock closed at $9.77…#tempesttherapeutics #tempest #tpst1120 #roche #otcqx #rhhby #morpheus
Source: Reuters: Health - Category: Consumer Health News Source Type: news